statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024

Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024 Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024 PR Newswire...

Federal Court Allows Vanda's HETLIOZ Patent Lawsuit to Proceed against Teva and Apotex

Federal Court Allows Vanda's HETLIOZ Patent Lawsuit to Proceed against Teva and Apotex Federal Court Allows Vanda's HETLIOZ Patent Lawsuit to Proceed against Teva and Apotex PR Newswire WASHINGTON...

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders

Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders Vanda Pharmaceuticals Board of...

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak PR...

Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.

Glancy Prongay & Murray LLP (GPM) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors and officers possible violations of state laws. If...

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.

Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd. Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication...

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference

Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference PR...

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY

Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY PR...

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

Vanda Pharmaceuticals Announces Presentations at SLEEP 2024 Vanda Pharmaceuticals Announces Presentations at SLEEP 2024 PR Newswire WASHINGTON, May 29, 2024 WASHINGTON, May 29, 2024 /PRNewswire...

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Volume	357,436.00
52-Wk High	$6.75
52-Wk Low	$3.30

VNDA Vanda Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals